Physician profile
Michael K Ditkoff
NPI 1235179995
$4,995.85
in general payments reported to CMS, 2019-2025
29 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 85% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $411 · 2021: $425 · 2022: $510 · 2023: $1,076 · 2024: $1,029 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,362 · Education: $88.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,362.47 |
| Education | $88.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,163.34 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,074.60 | 2021-2025 | Nucala |
| Optinose US, INC. | $523.45 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $300.09 | 2020-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $288.90 | 2021-2025 | Cuvitru, Elaprase |
| Aerin Medical INC. | $257.95 | 2021-2025 | |
| Neurent Medical Limited | $151.96 | 2023-2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Stryker Corporation | $138.25 | 2019-2025 | Xpress Loprofile, Clarifix, Shaver System |
| Hikma Pharmaceuticals USA | $125.96 | 2023-2025 | Ryaltris |
| Arrinex, INC. | $115.41 | 2019 | |
| Biotissue Holdings INC. | $99.60 | 2020 | |
| Medtronic, INC. | $98.52 | 2024 | Propel, Novapak, Nuvent |
| Ars Pharmaceuticals Operations, INC. | $91.17 | 2025 | Neffy |
| Csl Behring | $84.78 | 2024 | Haegarda |
| Acclarent, INC | $59.07 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.78 | 2023-2025 | Tezspire |
| Intersect Ent, INC. | $47.62 | 2020-2021 | |
| Inspire Medical Systems, INC. | $45.76 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $37.49 | 2023 | |
| Aytu Biopharma, INC. | $36.62 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $35.54 | 2023-2024 | Voquezna |
| Smith+Nephew, INC. | $33.72 | 2019-2021 | |
| Grifols USA, LLC | $23.81 | 2025 | Xembify |
| Pfizer INC. | $23.45 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.07 | 2025 | |
| Alk-Abello, INC | $17.60 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $15.93 | 2019 | |
| Oyster Point Pharma, INC. | $15.41 | 2022 | |
| Kaleo, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ditkoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.